Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs …
MX Li, H He, ZH Ruan, YX Zhu, RQ Li, X He, BH Lan… - BMC cancer, 2017 - Springer
Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …
[HTML][HTML] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
S Bhandari, N Dunlap, G Kloecker - Journal of Thoracic Disease, 2021 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations are present in 20–40% of non-small cell
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …
[HTML][HTML] Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of …
B Zhao, Y Wang, Y Wang, W Chen, L Zhou… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 …
SJ Park, HT Kim, DH Lee, KP Kim, SW Kim, C Suh… - Lung cancer, 2012 - Elsevier
Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell …
ZY He, MF Li, JH Lin, D Lin, RJ Lin - Cancer management and …, 2019 - Taylor & Francis
Background Non-small-cell lung cancer (NSCLC) is a global public health problem, and
brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy …
brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy …
Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor …
L Zhang, Y You, X Liu, F Liu, K Nie, Y Ji - Thoracic Cancer, 2023 - Wiley Online Library
Background The efficacy and safety of osimertinib combined with bevacizumab in non‐small
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
[HTML][HTML] Icotinib combined whole brain radiotherapy for patients with brain metastasis from lung adenocarcinoma harboring epidermal growth factor receptor mutation
JR Li, Y Zhang, JL Zheng - Journal of Thoracic Disease, 2016 - ncbi.nlm.nih.gov
Background The brain is a metastatic organ that is most prone to lung adenocarcinoma
(LAC). However, the prognosis of patients with brain metastasis remains very poor. In this …
(LAC). However, the prognosis of patients with brain metastasis remains very poor. In this …
[HTML][HTML] Comparative efficacy of systemic agents for brain metastases from non-small-cell lung cancer with an EGFR mutation/ALK rearrangement: a systematic review …
Background Brain metastases (BM) from non-small-cell lung cancer (NSCLC) are frequent
and carry significant morbidity, and current management options include varying local and …
and carry significant morbidity, and current management options include varying local and …
Progression of Central Nervous System metastases in Advanced Nonsmall Cell Lung Cancer patients effectively treated with first-generation epidermal growth factor …
M Yu, Q Zhao, Y Li, S Zhang, Y Xu, Y Gong… - Cancer Biotherapy & …, 2018 - liebertpub.com
Central nervous system (CNS) progression is frequently detected in patients with favorable
initial responses to first-generation epidermal growth factor receptor-tyrosine kinase …
initial responses to first-generation epidermal growth factor receptor-tyrosine kinase …